Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710488 | 0.84 | NOS3 (0.38) | CA2FFAR1CA12CA1CA4 | |
| SCHEMBL4062990 | 0.82 | ACACB (0.43) | ACACBCA2FFAR1FFAR4TSHR | |
| SCHEMBL15062693 | 0.81 | FFAR1 (0.35) | FFAR1FFAR4 | |
| SCHEMBL28047915 | 0.81 | FFAR1 (0.36) | FFAR1FFAR4 | |
| SCHEMBL16070697 | 0.80 | ACACB (0.49) | ACACBCA2TDP1FFAR1CYP4F2 | |
| SCHEMBL10535280 | 0.79 | HRH3 (0.37) | TDP1FFAR1TSHRALDH1A1 | |
| SCHEMBL7094308 | 0.79 | HSD17B10 (0.46) | CA2FFAR1FFAR4CA1TSHR | |
| SCHEMBL22862360 | 0.79 | CA2 (0.54) | ACACBCA2TDP1FFAR1CYP4F2 | |
| SCHEMBL18642578 | 0.79 | FFAR1 (0.66) | FFAR1FFAR4 | |
| SCHEMBL1306384 | 0.78 | GABRA1 (0.38) | TSHRKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235719-A1 | DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY | VIIV HEALTHCARE COMPANY (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | disclosed |
| US-20240294525-A1 | COMPOUNDS AS GLP-1 RECEPTOR AGONISTS AND USES THEREOF | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4406951-A1 | COMPOUND AS GLP-1 RECEPTOR AGONIST AND USE THEREOF | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023066356-A1 | COMPOUND AS GLP-1 RECEPTOR AGONIST AND USE THEREOF | 盛世泰科生物医药技术(苏州)有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-116003393-A | Compounds as GLP-1 receptor agonists and uses thereof | 盛世泰科生物医药技术(苏州)有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-10-14 | — | — | US | disclosed |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-10-14 | — | — | US | disclosed |
| US-20210149098-A1 | OPTICAL ELEMENT, METHOD FOR FORMING PHOTO-ALIGNMENT PATTERN, AND METHOD FOR MANUFACTURING OPTICAL ELEMENT | FUJIFILM CORPORATION (JP) | 2021-05-20 | — | — | US | disclosed |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210002556-A1 | COMPOUND, COMPOSITION, CURED OBJECT, OPTICALLY ANISOTROPIC BODY, AND REFLECTIVE FILM | FUJIFILM CORPORATION (JP) | 2021-01-07 | — | — | US | disclosed |
| WO-2018160967-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-09-07 | — | — | WO | disclosed |
| WO-2010043865-A1 | INHIBITORS OF HSP90 | CHROMA THERAPEUTICS LTD (GB) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294525-A1 | COMPOUNDS AS GLP-1 RECEPTOR AGONISTS AND USES THEREOF | GLP1R, GIPR, GPR119 | ACACB 1247/4885CA2 3590/4885TDP1 3616/4885 |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | ACACB 1578/4885CA2 4524/4885TDP1 2053/4885 |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | MELK, HIPK1, HIPK3 | ACACB 1440/4885CA2 4553/4885TDP1 2175/4885 |
| US-20210002556-A1 | COMPOUND, COMPOSITION, CURED OBJECT, OPTICALLY ANISOTROPIC BODY, AND REFLECTIVE FILM | MKI67, RB1, FLNA | ACACB 3830/4885CA2 3391/4885TDP1 4194/4885 |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | ACACB 1578/4885CA2 4524/4885TDP1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.